Abstract
We undertooka clinical evaluation of PG-501, 6, 6, 9-trimethyl-9-azabicyclo [3, 3, 1] non-3 β-yl α, α-di (2-thienyl) glycolate hydrochloride, in fourteen patients with Parkinsonism, two with headtremor and one with postural tremor, particularly to observe its effect on tremor.
Improvement in tremor was observed in 78% of the patients with Parkinsonism and in 100% of the others. The other symptoms of Parkinsonism, rigidity and akinesia, were improved in 3 of the fourteen patients, but 8 patients experienced improvement in tremor only.
Side effects encountered in certain cases consisted of nausea, anorexia, vertigo and headache, but they disappeared upon discontinuance of administration of PG-501.
We conclude that PG-501 is effective in improving tremor caused by Parkinsonism and other diseases.
